Analyst Price Targets — EXEL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 12, 2026 11:05 am | — | H.C. Wainwright | $54.00 | $42.94 | TheFly | Exelixis price target raised to $54 from $52 at H.C. Wainwright |
| February 11, 2026 12:11 pm | — | Stifel Nicolaus | $44.00 | $42.98 | TheFly | Exelixis price target raised to $44 from $43 at Stifel |
| February 4, 2026 10:46 am | Etzer Darout | Barclays | $44.00 | $42.59 | TheFly | Exelixis price target raised to $44 from $41 at Barclays |
| February 2, 2026 1:07 pm | Sean Laaman | Morgan Stanley | $49.00 | $41.29 | TheFly | Exelixis price target raised to $49 from $48 at Morgan Stanley |
| January 14, 2026 1:59 pm | — | Truist Financial | $51.00 | $44.65 | TheFly | Exelixis price target raised to $51 from $49 at Truist |
| January 8, 2026 2:30 pm | Robert Burns | H.C. Wainwright | $52.00 | $44.79 | TheFly | Exelixis price target raised to $52 from $49 at H.C. Wainwright |
| January 8, 2026 11:21 am | — | Morgan Stanley | $48.00 | $46.19 | TheFly | Exelixis downgraded to Equal Weight from Overweight at Morgan Stanley |
| January 5, 2026 11:11 am | — | UBS | $41.00 | $43.58 | StreetInsider | BofA Securities Downgrades Exelixis (EXEL) to Underperform |
| November 5, 2025 4:33 pm | Robert Burns | H.C. Wainwright | $49.00 | $40.52 | TheFly | Exelixis price target raised to $49 from $46 at H.C. Wainwright |
| November 5, 2025 12:52 pm | Stephen Willey | Stifel Nicolaus | $43.00 | $38.75 | TheFly | Exelixis price target raised to $43 from $41 at Stifel |
Latest News for EXEL
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis is looking to break out beyond its cabozantinib franchise. The company reported big earnings growth in 2025.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) EVP Dana Aftab sold 29,873 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $44.35, for a total transaction of $1,324,867.55. Following the completion of the transaction, the executive vice president owned 664,024 shares in
Hillsdale Investment Management Inc. grew its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 22.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,600 shares of the biotechnology company's stock after buying an additional 18,300 shares during the period. Hillsdale Investment Management Inc.'s
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EXEL.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.